ClinicalTrials.gg
TerminatedNCT06695741hypo-CASHUpdated Nov 4, 2026

Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia

A Phase 2 interventional study of Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy in Severe Aplastic Anemia, Cyclophosphamide Reduced-dose and Immunosuppressive Therapy, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Terminated at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
No significant improvement in efficacy was observed.
Updated Nov 4, 2026Now TerminatedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China — 16 open to participants now, 18 under way, none of them phase 3. Anemia, Aplastic · Institute of Hematology & Blood Diseases Hospital, China.

Enrollment
22nd of 25
14 · median 40
Started
2024
with 2 others
Phase 2
14 of 31
5 open now
Registered
19th of 31
by date

Among the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2024, is one of 14 in phase 2, and was the 19th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

16 of the 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anemia, Aplastic by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH) for severe aplastic anemia.

03

Conditions studied

  • Severe Aplastic Anemia
  • Cyclophosphamide Reduced-dose
  • Immunosuppressive Therapy

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a diagnosis of naïve severe or very severe aplastic anemia
  • Male or female age ≥ 12 years
  • Unwilling or unable to receive hematopoietic stem cell transplantation.
  • performance status ≤2
  • Willing and able to comply with the requirements for this study and written .

Exclusion criteria

Exclusion Criteria:

  • Previously received therapy > 4 weeks
  • Previously treated with TPO-RA > 4 weeks
  • Have an allergy or intolerance to anti-lymphocyte globulin, cyclosporine, herombopag or cyclophosphamide.
  • Uncontrolled fungal, bacterial, or viral infection. Hepatitis-associated aplastic anemia is allowed; or C infection is permitted unless it causes severe liver failure.
  • Tested positive for or syphilis
  • Presence of severe liver, kidney, or heart failure, or other life-threatening comorbidities.
  • History of radiotherapy and chemotherapy for malignant solid tumors in recent 5 years
  • Combined with other serious disorders
  • Pregnant or breast-feeding patients
  • Patients considered to be ineligible for the study by the investigator for reasons other than the above.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    hypo-CASH

    ALG/CsA and herombopag and reduced dose of cyclophosphamide

    Drug: Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy

Interventions

  • DrugReduced dose of cyclophosphamide combined with standard immunosuppressive therapy

    Severe aplastic anemia patients will receive a daily dose of Anti-lymphocyte globulin (25mg/kg) for the initial five days at the beginning of the treatment. Cyclosporine will be administered daily at a dosage of 3-5mg/kg. Herombopag will be administered daily at a dosage of 15mg starting from the first day of treatment and continuing for a duration of six months. Cyclophosphamide (20mg/kg) will be administered on days 15-16.

06

What researchers measure

Primary outcomes

  1. Overall response rate

    Percentage of patients with hematological response. Hematological response includes complete rate, near complete rate(CR), very good partial response(VGPR), good partial response(GPR) and partial response(PR).

    Time frame: Within 3 months

Secondary outcomes

  1. Superior response rate

    Percentage of patients with superior response, including CR, VGPR and GPR.

    Time frame: With in 6 months

  2. Overall response rate

    Percentage of patients with hematological response. Hematological response includes complete rate, near complete rate(CR), very good partial response(VGPR), good partial response(GPR) and partial response(PR).

    Time frame: With in 6 months

  3. Incidence of the adverse event

    Use Common Terminology Criteria for Adverse Events (CTCAE) Version 5 to assess the adverse event

    Time frame: Within 6 months

  4. Time to achieve robust superior response

    Time frame: Within 6 months

  5. First time to response

    Time frame: Within 6 months

07

Study locations

1 site
  • Red Blood Cell Disorders Center and Regenerative Medicine Center
    Tianjin, Tianjin Municipality 301617, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2024 to primary completion in May 2025, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Feb 2027 → May 2025 and completion Jun 2027 → Jun 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2024
First posted
Nov 19, 2024
StartActual
Nov 1, 2024
Primary completionActual
May 1, 2025was Feb 2027
CompletionActual
Jun 30, 2025was Jun 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated No significant improvement in efficacy was observed.
changed Nov 4, 2026
Sites
1 site added, 1 site removed
Show site
  • Red Blood Cell Disorders Center and Regenerative Medicine Center · Tianjin, China
Show 1 removed
  • Red Blood Cell Disorders Center and Regenerative Medicine Center · Tianjin, China
Nov 4, 2026
Primary completion
Feb 1, 2027→May 1, 2025 (actual)
Nov 4, 2026
Study completion
Jun 30, 2027→Jun 30, 2025 (actual)
Nov 4, 2026
Enrollment
75 (estimated)→14 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Terminated
    Why stopped No significant improvement in efficacy was observed.
    1 site added, 1 site removed
    Show site
    • Red Blood Cell Disorders Center and Regenerative Medicine Center · Tianjin, China
    Show 1 removed
    • Red Blood Cell Disorders Center and Regenerative Medicine Center · Tianjin, China
    Primary completion Feb 1, 2027→May 1, 2025 (now actual)
    Study completion Jun 30, 2027→Jun 30, 2025 (now actual)
    Enrollment 75 (estimated)→14 (actual)
    + 4 other changes: identifiers, verification date, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06695741
Responsible party
Jun Shi (Director of the Red Blood Cell Disorders Center & Director of the Regenerative Medicine Clinic, Institute of Hematology & Blood Diseases Hospital, China) — Principal investigator
First posted
Nov 19, 2024
Start date
Nov 1, 2024
Primary completion
May 1, 2025
Completion
Jun 30, 2025
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion